Treatment progress of interstitial lung disease with idiopathic inflammatory myopathies_West China Medical Journal

Authors：

LI Jing ¹ ,  LUO Fengming ²

1. Department of Respiratory and Critical Care Medicine, Jintang First People’s Hospital / Jintang Hospital, West China Hospital, Sichuan University, Chengdu, Sichuan 610400, P. R. China;
2. Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding?author：

LUO Fengming, Email: 790847157@qq.com

Keywords：

Interstitial lung disease; Idiopathic inflammatory myopathies; Treatment

DOI：

10.7507/1002-0179.201909140

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Interstitial lung disease is the most common pulmonary complication in patients with inflammatory myopathy, with a high case fatality rate, unknown pathogenesis, and complex clinical manifestations, and the treatment is difficult. Early and timely treatment can improve the patient’s clinical symptoms and inhibit the development of the disease. The present treatment protocols can be mainly summarized as the commonly used drugs (corticosteroids, azathioprine, cyclophosphamide, mycophenolate mofetil, and intravenous immunoglobulin) and new drugs (cyclosporin A, tacrolimus, biological agents, and anti-fibrosis drug), etc. In this paper, the treatment progress of inflammatory myopathy-related interstitial lung disease and different myositis antibody-related interstitial lung disease in recent years at home and abroad is reviewed, so as to provide a basis for clinical treatment.

Citation： LI Jing, LUO Fengming. Treatment progress of interstitial lung disease with idiopathic inflammatory myopathies. West China Medical Journal, 2021, 36(1): 114-119. doi: 10.7507/1002-0179.201909140 Copy

1.	Hallowell RW, Ascherman DP, Danoff SK. Pulmonary manifestations of polymyositis/dermatomyositis. Semin Respir Crit Care Med, 2014, 35(2): 239-248.
2.	Kawasumi H, Gono T, Kawaguchi Y, et al. Recent treatment of interstitial lung disease with idiopathic inflammatory myopathies. Clin Med Insights Circ Respir Pulm Med, 2015, 9(Suppl 1): 9-17.
3.	Lilleker JB, Vencovsky J, Wang G, et al. The EuroMyositis Registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis, 2018, 77(1): 30-39.
4.	Koreeda Y, Higashimoto I, Yamamoto M, et al. Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies. Intern Med, 2010, 49(5): 361-369.
5.	de Souza FHC, de Araújo DB, Vilela VS, et al. Guidelines of the Brazilian Society of Rheumatology for the treatment of systemic autoimmune myopathies. Adv Rheumatol, 2019, 59(1): 6.
6.	Shappley CL, Paik JJ, Saketkoo LA. Myositis-related interstitial lung diseases: diagnostic features, treatment, and complications. Curr Treatm Opt Rheumatol, 2019, 5(1): 56-83.
7.	Shimojima Y, Ishii W, Matsuda M, et al. Effective use of calcineurin inhibitor in combination therapy for interstitial lung disease in patients with dermatomyositis and polymyositis. J Clin Rheumatol, 2017, 23(2): 87-93.
8.	Ge Y, Peng Q, Zhang S, et al. Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review. Clin Rheumatol, 2015, 34(1): 99-105.
9.	Nakashima R, Mimori T. Anti-MDA5 (melanoma differentiation-associated gene 5) antibody and dermatomyositis with rapidly progressive interstitial pneumonia. Nihon Rinsho Meneki Gakkai Kaishi, 2013, 36(2): 71-76.
10.	Nagappa M, Taly AB, Sinha S, et al. Efficacy and limitations of pulse cyclophosphamide therapy in polymyositis and dermatomyositis. J Clin Neuromuscul Dis, 2013, 14(4): 161-168.
11.	Tieu J, Lundberg IE, Limaye V. Idiopathic inflammatory myositis. Best Pract Res Clin Rheumatol, 2016, 30(1): 149-168.
12.	Moghadam-Kia S, Aggarwal R, Oddis CV. Treatment of inflammatory myopathy: emerging therapies and therapeutic targets. Expert Rev Clin Immunol, 2015, 11(11): 1265-1275.
13.	Lega JC, Reynaud Q, Belot A, et al. Idiopathic inflammatory myopathies and the lung. Eur Respir Rev, 2015, 24(136): 216-238.
14.	Aggarwal R, Oddis CV. Therapeutic advances in myositis. Curr Opin Rheumatol, 2012, 24(6): 635-641.
15.	Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol, 2013, 40(5): 640-646.
16.	Mira-Avendano IC, Parambil JG, Yadav R, et al. A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis. Respir Med, 2013, 107(6): 890-896.
17.	Go DJ, Park JK, Kang EH, et al. Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease. Rheumatol Int, 2016, 36(1): 125-131.
18.	Barba T, Fort R, Cottin V, et al. Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta-analysis. Autoimmun Rev, 2019, 18(2): 113-122.
19.	Nagasaka K, Harigai M, Tateishi M, et al. Efficacy of combination treatment with cyclosporin A and corticosteroids for acute interstitial pneumonitis associated with dermatomyositis. Mod Rheumatol, 2003, 13(3): 231-238.
20.	Cavagna L, Caporali R, Abdì-Alì L, et al. Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease. J Rheumatol, 2013, 40(4): 484-492.
21.	Kurita T, Yasuda S, Amengual O, et al. The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis/dermatomyositis. Lupus, 2015, 24(1): 3-9.
22.	Witt LJ, Demchuk C, Curran JJ, et al. Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease. Pulm Pharmacol Ther, 2016, 36(36): 46-52.
23.	Ge Y, Zhou H, Shi J, et al. The efficacy of tacrolimus in patients with refractory dermatomyositis/polymyositis: a systematic review. Clin Rheumatol, 2015, 34(12): 2097-2103.
24.	Andersson H, Sem M, Lund MB, et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology (Oxford), 2015, 54(8): 1420-1428.
25.	Keir GJ, Maher TM, Ming D, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology, 2014, 19(3): 353-359.
26.	Bauhammer J, Blank N, Max R, et al. Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response. J Rheumatol, 2016, 43(8): 1566-1574.
27.	Li T, Guo L, Chen Z, et al. Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. Sci Rep, 2016, 6: 33226.
28.	施善芬, 黎良達, 潘翠萍, 等. 伊馬替尼治療多發性肌炎/皮肌炎合并間質性肺炎患者的療效分析. 現代實用醫學, 2017, 29(8): 994-996.
29.	Hallowell RW, Amariei D, Danoff SK. Intravenous immunoglobulin as potential adjunct therapy for interstitial lung disease. Ann Am Thorac Soc, 2016, 13(10): 1682-1688.
30.	Giannini M, Fiorella ML, Tampoia M, et al. Long-term efficacy of adding intravenous immunoglobulins as treatment of refractory dysphagia related to myositis: a retrospective analysis. Rheumatology (Oxford), 2020: keaa443.
31.	Chambers DC, Yusen RD, Cherikh WS, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Lung and Heart-Lung Transplantation Report-2017; focus theme: allograft ischemic time. J Heart Lung Transplant, 2017, 36(10): 1047-1059.
32.	Ameye H, Ruttens D, Benveniste O, et al. Is lung transplantation a valuable therapeutic option for patients with pulmonary polymyositis? Experiences from the Leuven transplant cohort. Transplant Proc, 2014, 46(9): 3147-3153.
33.	Betteridge Z, Mchugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med, 2016, 280(1): 8-23.
34.	胡譯丹, 劉鋼, 謝其冰. 特發性炎性肌病相關的間質性肺疾病. 華西醫學, 2018, 33(12): 1544-1548.
35.	Hervier B, Devilliers H, Stanciu R, et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev, 2012, 12(2): 210-217.
36.	Hamaguchi Y, Fujimoto M, Matsushita T, et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One, 2013, 8(4): e60442.
37.	Oddis CV, Aggarwal R. Treatment in myositis. Nat Rev Rheumatol, 2018, 14(5): 279-289.
38.	So H, Ip RW, Wong VT, et al. Analysis of anti-melanoma differentiation-associated gene 5 antibody in Hong Kong Chinese patients with idiopathic inflammatory myopathies: diagnostic utility and clinical correlations. Int J Rheum Dis, 2018, 21(5): 1076-1081.
39.	王怡, 李穎, 李升錦. 抗 MDA5 抗體對成年及幼年型皮肌炎合并間質性肺病診斷效能的 meta 分析. 臨床檢驗雜志, 2018, 36(1): 46-52.
40.	Koguchi-Yoshioka H, Okiyama N, Iwamoto K, et al. Intravenous immunoglobulin contributes to the control of antimelanoma differentiation-associated protein 5 antibody-associated dermatomyositis with palmar violaceous macules/papules. Br J Dermatol, 2017, 177(5): 1442-1446.
41.	Watanabe R, Ishii T, Araki K, et al. Successful multi-target therapy using corticosteroid, tacrolimus, cyclophosphamide, and rituximab for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis. Mod Rheumatol, 2016, 26: 465-466.
42.	Hengstman GJ, Ter Laak HJ, Vree Egberts WT, et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis, 2006, 65(12): 1635-1638.
43.	Cottin V, Thivolet-Béjui F, Reynaud-Gaubert M, et al. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J, 2003, 22(2): 245-250.
44.	Suzuki S, Nishikawa A, Kuwana M, et al. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis, 2015, 10: 61.
45.	Garcia-Rosell M, Moore S, Pattanaik D, et al. Signal recognition antibody-positive myopathy and response to intravenous immunoglobulin G (IVIG). J Clin Rheumatol, 2013, 19(4): 214-217.
46.	Watanabe Y, Uruha A, Suzuki S, et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry, 2016, 87(10): 1038-1044.

1. Hallowell RW, Ascherman DP, Danoff SK. Pulmonary manifestations of polymyositis/dermatomyositis. Semin Respir Crit Care Med, 2014, 35(2): 239-248.
2. Kawasumi H, Gono T, Kawaguchi Y, et al. Recent treatment of interstitial lung disease with idiopathic inflammatory myopathies. Clin Med Insights Circ Respir Pulm Med, 2015, 9(Suppl 1): 9-17.
3. Lilleker JB, Vencovsky J, Wang G, et al. The EuroMyositis Registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis, 2018, 77(1): 30-39.
4. Koreeda Y, Higashimoto I, Yamamoto M, et al. Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies. Intern Med, 2010, 49(5): 361-369.
5. de Souza FHC, de Araújo DB, Vilela VS, et al. Guidelines of the Brazilian Society of Rheumatology for the treatment of systemic autoimmune myopathies. Adv Rheumatol, 2019, 59(1): 6.
6. Shappley CL, Paik JJ, Saketkoo LA. Myositis-related interstitial lung diseases: diagnostic features, treatment, and complications. Curr Treatm Opt Rheumatol, 2019, 5(1): 56-83.
7. Shimojima Y, Ishii W, Matsuda M, et al. Effective use of calcineurin inhibitor in combination therapy for interstitial lung disease in patients with dermatomyositis and polymyositis. J Clin Rheumatol, 2017, 23(2): 87-93.
8. Ge Y, Peng Q, Zhang S, et al. Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review. Clin Rheumatol, 2015, 34(1): 99-105.
9. Nakashima R, Mimori T. Anti-MDA5 (melanoma differentiation-associated gene 5) antibody and dermatomyositis with rapidly progressive interstitial pneumonia. Nihon Rinsho Meneki Gakkai Kaishi, 2013, 36(2): 71-76.
10. Nagappa M, Taly AB, Sinha S, et al. Efficacy and limitations of pulse cyclophosphamide therapy in polymyositis and dermatomyositis. J Clin Neuromuscul Dis, 2013, 14(4): 161-168.
11. Tieu J, Lundberg IE, Limaye V. Idiopathic inflammatory myositis. Best Pract Res Clin Rheumatol, 2016, 30(1): 149-168.
12. Moghadam-Kia S, Aggarwal R, Oddis CV. Treatment of inflammatory myopathy: emerging therapies and therapeutic targets. Expert Rev Clin Immunol, 2015, 11(11): 1265-1275.
13. Lega JC, Reynaud Q, Belot A, et al. Idiopathic inflammatory myopathies and the lung. Eur Respir Rev, 2015, 24(136): 216-238.
14. Aggarwal R, Oddis CV. Therapeutic advances in myositis. Curr Opin Rheumatol, 2012, 24(6): 635-641.
15. Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol, 2013, 40(5): 640-646.
16. Mira-Avendano IC, Parambil JG, Yadav R, et al. A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis. Respir Med, 2013, 107(6): 890-896.
17. Go DJ, Park JK, Kang EH, et al. Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease. Rheumatol Int, 2016, 36(1): 125-131.
18. Barba T, Fort R, Cottin V, et al. Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta-analysis. Autoimmun Rev, 2019, 18(2): 113-122.
19. Nagasaka K, Harigai M, Tateishi M, et al. Efficacy of combination treatment with cyclosporin A and corticosteroids for acute interstitial pneumonitis associated with dermatomyositis. Mod Rheumatol, 2003, 13(3): 231-238.
20. Cavagna L, Caporali R, Abdì-Alì L, et al. Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease. J Rheumatol, 2013, 40(4): 484-492.
21. Kurita T, Yasuda S, Amengual O, et al. The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis/dermatomyositis. Lupus, 2015, 24(1): 3-9.
22. Witt LJ, Demchuk C, Curran JJ, et al. Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease. Pulm Pharmacol Ther, 2016, 36(36): 46-52.
23. Ge Y, Zhou H, Shi J, et al. The efficacy of tacrolimus in patients with refractory dermatomyositis/polymyositis: a systematic review. Clin Rheumatol, 2015, 34(12): 2097-2103.
24. Andersson H, Sem M, Lund MB, et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology (Oxford), 2015, 54(8): 1420-1428.
25. Keir GJ, Maher TM, Ming D, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology, 2014, 19(3): 353-359.
26. Bauhammer J, Blank N, Max R, et al. Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response. J Rheumatol, 2016, 43(8): 1566-1574.
27. Li T, Guo L, Chen Z, et al. Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. Sci Rep, 2016, 6: 33226.
28. 施善芬, 黎良達, 潘翠萍, 等. 伊馬替尼治療多發性肌炎/皮肌炎合并間質性肺炎患者的療效分析. 現代實用醫學, 2017, 29(8): 994-996.
29. Hallowell RW, Amariei D, Danoff SK. Intravenous immunoglobulin as potential adjunct therapy for interstitial lung disease. Ann Am Thorac Soc, 2016, 13(10): 1682-1688.
30. Giannini M, Fiorella ML, Tampoia M, et al. Long-term efficacy of adding intravenous immunoglobulins as treatment of refractory dysphagia related to myositis: a retrospective analysis. Rheumatology (Oxford), 2020: keaa443.
31. Chambers DC, Yusen RD, Cherikh WS, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Lung and Heart-Lung Transplantation Report-2017; focus theme: allograft ischemic time. J Heart Lung Transplant, 2017, 36(10): 1047-1059.
32. Ameye H, Ruttens D, Benveniste O, et al. Is lung transplantation a valuable therapeutic option for patients with pulmonary polymyositis? Experiences from the Leuven transplant cohort. Transplant Proc, 2014, 46(9): 3147-3153.
33. Betteridge Z, Mchugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med, 2016, 280(1): 8-23.
34. 胡譯丹, 劉鋼, 謝其冰. 特發性炎性肌病相關的間質性肺疾病. 華西醫學, 2018, 33(12): 1544-1548.
35. Hervier B, Devilliers H, Stanciu R, et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev, 2012, 12(2): 210-217.
36. Hamaguchi Y, Fujimoto M, Matsushita T, et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One, 2013, 8(4): e60442.
37. Oddis CV, Aggarwal R. Treatment in myositis. Nat Rev Rheumatol, 2018, 14(5): 279-289.
38. So H, Ip RW, Wong VT, et al. Analysis of anti-melanoma differentiation-associated gene 5 antibody in Hong Kong Chinese patients with idiopathic inflammatory myopathies: diagnostic utility and clinical correlations. Int J Rheum Dis, 2018, 21(5): 1076-1081.
39. 王怡, 李穎, 李升錦. 抗 MDA5 抗體對成年及幼年型皮肌炎合并間質性肺病診斷效能的 meta 分析. 臨床檢驗雜志, 2018, 36(1): 46-52.
40. Koguchi-Yoshioka H, Okiyama N, Iwamoto K, et al. Intravenous immunoglobulin contributes to the control of antimelanoma differentiation-associated protein 5 antibody-associated dermatomyositis with palmar violaceous macules/papules. Br J Dermatol, 2017, 177(5): 1442-1446.
41. Watanabe R, Ishii T, Araki K, et al. Successful multi-target therapy using corticosteroid, tacrolimus, cyclophosphamide, and rituximab for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis. Mod Rheumatol, 2016, 26: 465-466.
42. Hengstman GJ, Ter Laak HJ, Vree Egberts WT, et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis, 2006, 65(12): 1635-1638.
43. Cottin V, Thivolet-Béjui F, Reynaud-Gaubert M, et al. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J, 2003, 22(2): 245-250.
44. Suzuki S, Nishikawa A, Kuwana M, et al. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis, 2015, 10: 61.
45. Garcia-Rosell M, Moore S, Pattanaik D, et al. Signal recognition antibody-positive myopathy and response to intravenous immunoglobulin G (IVIG). J Clin Rheumatol, 2013, 19(4): 214-217.
46. Watanabe Y, Uruha A, Suzuki S, et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry, 2016, 87(10): 1038-1044.

West China Medical Journal

Treatment progress of interstitial lung disease with idiopathic inflammatory myopathies

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content